Sanofi MS Drug Meets Trial Goal of Reducing Disability
Sanofi’s experimental multiple sclerosis drug has shown promising results in a late-stage trial, delaying disability progression in patients and paving the way for discussions with regulators about potentially bringing it to market.
Sanofi’s experimental multiple sclerosis drug has shown promising results in a late-stage trial, delaying disability progression in patients and paving the way for discussions with regulators about potentially bringing it to market.
